VivaMed BioPharma teams up with Syngene International to fast-track AI-driven drug programmes
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen
Dr Adams’ lab recently uncovered a novel cellular detoxification pathway driving Cisplatin resistance in NSCLC
Subscribe To Our Newsletter & Stay Updated